Objective: To evaluate elvitegravir and cobicistat pharmacokinetics during pregnancy compared with postpartum and in infant washout samples after delivery.
Introduction
Integrase strand transfer inhibitors (INSTI) are a potent class of antiretrovirals which target the HIV integrase enzyme and block incorporation of viral HIV-1 DNA into the host cell genome. INSTIs are currently recommended as first-line treatment for antiretroviralnaive adults and children in the United States living with HIV [1, 2] . Although safe and effective antiretroviral treatment options continue to increase, data on newer agents for use in pregnant women remain sparse. Antiretroviral treatment is widely used for HIV-infected pregnant women both as primary treatment of maternal HIV infection and to prevent mother-to-child HIV transmission. Physiological changes during pregnancy have a substantial impact on drug disposition which may affect exposure to antiretrovirals and subsequently dosing requirements [3, 4] . For example, drugs metabolized by the cytochrome P450 3A (CYP3A) enzyme family, such as protease inhibitors, often show decreased exposure during pregnancy [5] [6] [7] [8] . Exposure to other antiretrovirals during pregnancy is generally decreased to a lesser extent, with the exception of etravirine exposure which is increased during pregnancy [9] . Lower antiretroviral exposure increases the risk of inadequate maternal suppression of HIV replication and transmission of HIV to the infant, while increased drug exposure may subject mother and child to increased risk of drug toxicities [10] .
Elvitegravir is a second generation INSTI indicated for HIV-1 infection in combination with other antiretroviral drugs. Elvitegravir is primarily metabolized by CYP3A-mediated metabolism with additional glucuronidation of the hydroxylated metabolite by UGT1A1 and UGT1A3 [11] . In clinical practice, elvitegravir is coadministered with the pharmacokinetic enhancer cobicistat, a potent mechanism-based inhibitor of CYP3A, to increase elvitegravir exposure and facilitate once-daily dosing. Cobicistat is primarily metabolized by CYP3A and to a minor extent by CYP2D6 [12] . Elvitegravir is available in two fixed-dose combination (FDC) tablets containing elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg, and either tenofovir disoproxil fumarate (TDF) 300 mg or tenofovir alafenamide (TAF) 10 mg.
Two prior case reports have described elvitegravir and cobicistat pharmacokinetics during pregnancy and postpartum in individual patients. In both cases, evitegravir and cobicistat exposure were considerably lower during pregnancy than reference values in nonpregnant patients [13, 14] . A separate study in pregnant women taking elvitegravir as part of a FDC showed detectable elvitegravir concentrations in cord blood and placental cells suggesting transfer to the fetal circulation [15] . The Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission, convened by the Office of AIDS Research Advisory Committee and supported by the Health Resources and Services Administration and the National Institutes of Health, currently classifies elvitegravir/cobicistat as 'Not Recommended for Initial Use in Pregnancy' based upon preliminary data showing inadequate levels of both drugs during the second and third trimester as well as viral breakthroughs [10] . The primary objective of this study was to characterize the pharmacokinetics of elvitegravir and cobicistat during pregnancy and postpartum in HIV-1-infected women.
Methods
Study population and design IMPAACT P1026s 'Pharmacokinetic Properties of Antiretroviral and Related Drugs during Pregnancy and Postpartum' (ClinicalTrials.gov NCT00042289), is an ongoing nonrandomized, open-label, parallel-group, multicenter, phase IV prospective study. The study recruited pregnant HIV-infected women at least 20 weeks gestation receiving elvitegravir and cobicistat in combination with emtricitabine and TDF (Stribild; Gilead Sciences, Inc., Foster City, California, USA) or TAF (Genvoya; Gilead Sciences, Inc.) once daily prescribed for clinical care. All participants were from the United States. Participants had to be stable on their antiretroviral regimen for 2 weeks and intend to continue the same regimen through 6-12 weeks postpartum. Maternal exclusion criteria were multiple gestation, a clinical or laboratory toxicity necessitating a medication change during the study, and the use of specific medications known to interact with elvitegravir or cobicistat.
Each study site received ethical and local institutional review board approval. All participants gave informed consent prior to study participation. Medications were prescribed by each participant's clinical care provider. Pharmacokinetic sampling was performed during the second trimester, third trimester, and postpartum. Collected samples were assayed in real time and results reported to each study participant and her clinician.
Infant enrollment occurred immediately after maternal enrollment with maternal consent, with eligibility confirmed at birth. Infant inclusion criteria were birth weight more than 1000 g, singleton delivery and maternal enrollment in P1026s. Infant exclusion criteria were a severe congenital malformation or medical condition that would interfere with study participation as deemed by site clinicians and use of specific medications known to interfere with elvitegravir disposition.
Clinical and laboratory monitoring
Each study visit included monitoring of HIV-1 RNA, CD4 þ lymphocyte cell count, hematology, and serum biochemistry. The lower limit of detection for HIV-1 RNA assays performed locally ranged from 50 to 400 copies/ml. All infants received physical examinations after birth and laboratory evaluations were performed if clinically indicated. Adverse events were reported at each study visit and management was determined by each participant's clinician. The National Institute of Allergy and Infectious Diseases, Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events was used to grade adverse event severity.
Sample collection
Intensive 24-h pharmacokinetic evaluations were performed during the second trimester (20-26 weeks gestation), third trimester (30-38 weeks gestation) and postpartum (6-12 weeks following delivery). Requirements prior to pharmacokinetic sampling were selfreported elvitegravir and cobicistat adherence for 2 weeks and consistent dosing times for the last 3 days. Elvitegravir and cobicistat were dosed with food. On sampling days the predose sample was drawn and study medications were administered under observation. Postdose samples were drawn at 1, 2, 4, 6, 8, 12, and 24 h. At delivery, cord blood and maternal plasma samples were collected when possible. In infants, four plasma samples were collected at 2-10, 18-28, 36-72 h, and 5-9 days after birth. ) linear regression analysis of the elvitegravir/internal standards or cobicistat/internal standards peak area ratio versus the respective elvitegravir or cobicistat concentration from 10.00 to 5000 ng/ml. Concentrations of incurred and quality control samples are calculated with the same regression analysis.
Pharmacokinetic analyses
Elvitegravir and cobicistat maximum, minimum, and last plasma concentrations (C max , C min , C 24 ) along with corresponding time points (T max , T min ) were observed directly. Steady-state area under the concentration versus time curve from time 0 to 24 h postdose (AUC 0-24 ) was estimated with the trapezoidal rule. Half-life (t 1/2 ) was calculated as 0.693/l z where l z is the elimination rate constant derived from the terminal slope of the log concentration versus time curve. For participants with predose concentrations below the assay quantification limit, single-dose AUC from time 0 to infinity was estimated as AUC 0-24 and the C 24 divided by l z . Apparent oral clearance (CL/F) was calculated as dose divided by AUC 0-24 . Undetectable concentrations were set at half the lower limit of quantification to calculate summary statistics. Absorption lags were defined as 1-h postdose concentrations that were lower than observed predose concentrations. The minimum exposure target for elvitegravir was the 10th percentile AUC 0-24 in nonpregnant HIVinfected patients (16 100 ngÁh/ml), which was estimated from published pharmacokinetic parameters [16] .
Statistical analyses
The target sample size was 25 women with evaluable third trimester pharmacokinetic data, with at least 12 who had evaluable second trimester pharmacokinetic data. Each individual woman's elvitegravir exposure during pregnancy was determined in real time, compared with the 50th and 10th percentile AUCs estimated for nonpregnant adult historical controls, and reported to each participant's care provider.
Descriptive statistics were calculated for pharmacokinetic parameters during each study period. Pharmacokinetic parameters during the second trimester versus postpartum and during the third trimester versus postpartum were compared at the within-participant level using the Wilcoxon signed-rank test, with a two-sided P of 0.10 or less considered statistically significant. Within-participant geometric mean ratios (GMR) and 90% confidence intervals (CIs) for pharmacokinetic parameters in the pregnant versus nonpregnant conditions were calculated for elvitegravir and cobicisistat to estimate the range of percentage changes between the two conditions that would be consistent with the observed data and assess clinical importance, to inform dosing recommendations. The body weights of participants who met or did not meet the elvitegravir AUC 0-24 target in each study period were compared using the Mann-Whitney U test. Elvitegravir AUC 0-24 and C 24 in participants with or without viral suppression, defined in this study as HIV-1 RNA of 50 copies/ml or less, were also compared using the Mann-Whitney U test.
Results

Participant characteristics
Thirty pregnant women taking elvitegravir and cobicistat once-daily enrolled in the study. Paired pregnancy and postpartum data were available for 14 of 17 women who had second trimester visits and for 24 of 26 women who had third trimester visits. Two mothers withdrew from the study before delivery and follow-up is available for 28 infants. Maternal and infant clinical characteristics are summarized in Table 1 .
Elvitegravir pharmacokinetics
Median [interquartile range (IQR)] elvitegravir AUC 0-24 in the second trimester, third trimester and postpartum periods were 15 283 ngÁh/ml (11 939-19 038), 14 004 ngÁh/ml (9119-18 798) and 21 039 ngÁh/ml (13 532-32 788), respectively. Compared with paired postpartum data, elvitegravir AUC 0-24 was 24% lower in the second trimester (n ¼ 14, P ¼ 0.06, GMR ¼ 0.76, 90% CI 0.57-1.0) and 44% lower in the third trimester (n ¼ 24, P ¼ 0.0001, GMR ¼ 0.56, 90% CI 0.42-0.73) ( Table 2 , Fig. 1 ). The frequency of participants meeting the target AUC 0-24 of 16 100 ngÁh/ml was eight of 2510 AIDS 2018, Vol 32 No 17 Elvitegravir C max was not significantly different in the second trimester compared with paired postpartum data but was 28% lower in the third trimester (P ¼ 0.36 and 0.02, respectively). Elvitegravir C 24 was 81% lower in the second trimester and 89% lower in the third trimester compared with paired postpartum data (P ¼ 0.009 and 0.0001, respectively). Lags in absorption were seen in four of 17 (24%), three of 26 (12%), and seven of 25 (28%) women in the second trimester, third trimester, and postpartum, respectively. Fig. 1 ).
Cobicistat AUC was negatively associated with elvitegravir apparent CL/F (Fig. 3 ).
Cobicistat C max was 28% lower in the second trimester and 38% lower in the third trimester compared with paired postpartum data (P ¼ 0.08 and 0.02, respectively). Cobicistat C 24 was 60% lower in the second trimester No plasma samples had quantifiable elvitegravir concentrations at the final washout sample (between 5 and 9 days of life). Samples below the lower limit of quantitation of the assay (10 ng/ml) are shown as 1/2 lower limit of quantitation (5 ng/ml). Cord blood samples were obtained from 15 women at delivery. Of those, cobicistat concentrations were below the quantitation limit in eight samples. Of the remaining samples, cobicistat concentrations in cord blood ranged between 11.1 and 110.6 ng/ml with a median of 35.3 ng/ ml. The median concentration of cobicistat in maternal plasma at delivery was 172.4 ng/ml. A total of seven women had cord blood and maternal plasma at delivery obtained with cobicistat concentrations above the limit of quantitation in each. In those participants, the median ratio (IQR) of cord blood to maternal plasma was 0.09 (0.05-0.12). Cobicistat was not detected in any neonatal plasma samples after birth (Table 4) .
Maternal and infant outcomes
Preterm labor, classified as possibly treatment related, occurred in one woman.
Congenital anomalies that were classified as possibly treatment related occurred in two of 26 infants: one infant with amniotic band syndrome, microcephaly, and intrauterine growth restriction and one infant with ulnar postaxial polydactyly.
The percentage of women with suppression of HIV replication (viral suppression, defined in this study as HIV-1 RNA 50 copies/ml), at the second trimester, third trimester, delivery, and postpartum was 76.5, 92.3, 76, and 76%, respectively. No correlation was observed between viral suppression and elvitegravir exposure.
Discussion
Increasing use of INSTIs as first-line treatment regimens for adults living with HIV, particularly in resource-rich settings, will lead to more pregnancies occurring in women on elvitegravir and cobicistat-containing regimens. This study is the first to analyze the Elvitegravir/cobicistat pregnancy pharmacokinetics Momper et al. 2513 Table 4 . Elvitegravir and cobicistat exposure at delivery and in infants, median (interquartile range). Maximum observed concentration (ng/ml) 161.0 (31.0, 373.5) Concentration (2-10 h, ng/ml) 131.9 (24.4, 396.0) Concentration (18-28 h, ng/ml) 31.9 (11.5, 87.9) Concentration (36-72 h, ng/ml) <10 (<10-10.5) Concentration (5-9 days, ng/ml) <10 (<10-<10) T 1/2 (h) 7.6 (6.3, 10.2) a Calculated in 12 patients for whom both cord blood and maternal plasma samples were obtained at time of delivery with quantifiable elvitegravir concentrations (>10 ng/ml). Calculated in seven patients for whom both cord blood and maternal plasma samples were obtained at time of delivery with quantifiable cobicistat concentrations (>10 ng/ml). pharmacokinetics of elvitegravir boosted with cobicistat in a large population of pregnant HIV-infected women receiving elvitegravir and cobicistat in combination with emtricitabine and TDF (STRIBILD; Gilead Sciences, Inc.) or TAF (GENVOYA; Gilead Sciences, Inc.). TAF has not been extensively studied during pregnancy and is not currently recommended for initiation in pregnant women in the current guidelines by the Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission [10] . Although women in this study may have received either TDF or TAF, neither drug is expected to alter the pharmacokinetics of elvitegravir or cobicistat [17, 18] .
Compared with paired postpartum data, elvitegravir AUC 0-24 was 24% lower in the second trimester and 44% lower in the third trimester, whereas C 24 was 81% lower in the second trimester and 89% lower in the third trimester. Postpartum elvitegravir exposure at 6-12 weeks following delivery was comparable with that of nonpregnant adults (Table 2 ). Subtherapeutic antiretroviral exposure during pregnancy may increase the risk of virologic failure in the mother and mother-to-child HIV transmission. In this study, subtherapeutic elvitegravir exposure was defined as less than the 10th percentile elvitegravir AUC 0-24 (16 100 ngÁh/ml) of nonpregnant adults [16] . Fewer participants met this minimum threshold during pregnancy (47% in second trimester; 38% in third trimester) compared with postpartum (72%).
Prior analyses of the relationship between elvitegravir exposure and virologic outcome have been performed using data from Phase III trials conducted during drug development. In 373 treatment-naïve adult participants administered elvitregravir/cobicistat/emtricitabine/TDF FDC, a relatively 'flat' relationship was observed between elvitegravir exposure (C 0 and AUC 0-24 ) and the percentage of participants achieving virologic success (viral load <50 HIV-1 RNA copies/ml) [19] . However, the median C 0 in the lowest decile (156 ng/ml) was well above the C 0 observed in this study during the second trimester (18 ng/ml) and third trimester (25.1 ng/ml) of pregnancy.
Although Food and Drug Administration (FDA) bioequivalence criteria typically include evaluation of only AUC and C max , maintaining high trough concentrations is critically important for INSTIs as these agents display antiviral activity only when their plasma concentrations are continually maintained above a minimum threshold. Elvitegravir does not exhibit intracellular persistence associated with nucleoside reverse transcriptase inhibitors such as tenofovir and protects cells from viral rechallenge only when concentrations are maintained above the concentration which inhibits viral suppression by 95% (EC 95 ) [11] . These in-vitro findings are translatable to clinical pharmacokinetic-pharmacodynamic relationships, where elvitegravir C min values are more closely correlated with antiviral activity than C max or AUC. In exposure-response analyses, C min values but not C max or AUC were capable of fitting an E max model, where effect is defined as the log 10 maximum change in HIV-1 RNA [20] . Thus, the virologic potency of elvitegravir as a boosted antiretroviral is in part due to the substantially higher C min achieved with ritonavir or cobicistat relative to unboosted elvitegravir. Notably, elvitegravir median C min concentrations at both the second and third trimesters were below the protein binding-adjusted EC 95 of 45 ng/ml [21] . Postpartum AUC and C max in this study were similar to previously reported values in nonpregnant adults.
Physiologic changes in pregnancy likely contribute to the observed altered pharmacokinetics of elvitegravir and cobicistat. Increases in blood volume, total body water, and body mass can have a dilutional effect on drug concentrations and plasma proteins. Higher production of several hormones, such as progesterone, induce metabolic enzymes, including CYP3A. Changes in gastrointestinal tract function, including gastric pH and hepatic plasma flow, can affect drug absorption, distribution, metabolism and excretion. The metabolism of both elvitegravir and cobicistat is primarily by CYP3A which is localized in the liver, intestine, uterus, placenta, and elsewhere [22, 23] . Hormones such as placental growth hormone, estrogen, cortisol, and progesterone induce a two-fold increase in CYP3A activity [24] . Increases in CYP3A metabolism may contribute to decreased exposure to both drugs during pregnancy. Further, cobicistat is used as a pharmacokinetic enhancer to inhibit CYP3A-mediated metabolism of elvitegravir, thereby increasing elvitegravir systemic exposure. In this study, cobicistat exposure was 44% lower during the second trimester and 59% lower during the third trimester relative to paired postpartum data. The reduction in elvitegravir exposure during pregnancy may result from pregnancy related changes in elvitegravir drug disposition (reduced absorption, increased volume of distribution or increased metabolism) or less cobicistat boosting from lower plasma cobicistat concentrations, or both.
Elvitegravir apparent CL/F was negatively correlated with cobicistat AUC and this effect was more prounouced in the second trimester and third trimester, where cobicistat AUC 0-24 was 44% lower and 59% lower compared with paired postpartum data, respectively. No obvious relationship was seen between elvitegravir halflife and cobicistat exposure, suggesting that the higher CL/F in patients with low cobicistat AUC may be driven in large part by reduced elvitegravir oral bioavailability. In addition, a prior population pharmacokinetic study of elvitegravir and cobicistat in 144 nonpregnant HIV-1-infected patients estimated that a reduction in cobicistat AUC of 25, 50, and 75% would reduce elvitegravir exposure by 38.0, 117.3, and 372.4%, respectively [25] .
Elvitegravir is highly protein-bound in plasma (98-99%), primarily to albumin [26] . The concentration of albumin is decreased in pregnancy. In addition, drug binding to albumin may be displaced by increased hormone binding to this protein during pregnancy. Although the unbound fraction is responsible for pharmacologic activity, unbound concentrations were not measured in this study. Although lower elvitegravir exposure was observed during pregnancy, the therapeutic unbound free fraction during pregnancy is unknown.
The current study determined the washout kinetics of elvitegravir transferred in-utero across the placenta in infants born to mothers receiving elvitegravir during pregnancy. The median ratio of the elvitegravir concentration in cord blood/maternal plasma at delivery was 0.91, suggesting high placental transfer. The median elimination half-life in 23 infants was 7.54 h which is similar to that of nonpregnant adults. Cobicistat was not detected above the quantitation limit of the assay in any neonatal plasma samples. A longer elimination half-life would be expected if elvitegravir were to be administered to infants with cobicistat.
Adherence was not directly measured in the study. Predose elvitegravir trough levels (C 0 ) below the lower limit of quantitation (LLOQ) of the assay (10 ng/ml) may be suggestive of nonadherence. In the second trimester, three of 17 women (17.6%) had predose trough concentrations below the LLOQ. In the third trimester and postpartum, seven of 26 women (26.9%) and three of 25 women (12%), respectively, had predose trough levels below the LLOQ. However, C 24 concentrations below or near the LLOQ were also noted in some women following an observed elvitegravir dose. Overall, the number of study participants who had a predose trough concentration below the LLOQ and a C 24 at least twice the LLOQ was three of 17 in the second trimester, three of 26 in the third trimester, and three of 25 postpartum. These results suggest that the observed changes in elvitegravir pharmacokinetics in this study are true pregnancy-related effects and do not represent nonadherence.
A limitation of this study is that recruitment of women already taking elvitegravir and cobicistat may result in a study population that is more likely to respond to the regimen without treatment-limiting adverse effects. This selection bias may overestimate positive outcomes and underestimate adverse events. Another limitation is that meals at the time of dosing were not standardized in terms of size and fat content. Prior studies have shown that, relative to fasting, a light meal ($373 kcal, 20% fat) results in 34% higher elvitegravir exposure (90% CI: 19-51%) while a heavy meal ($800 kcal, 50% fat) results in 87% higher elvitegravir exposure (90% CI: 66-110%) [11] . It is also possible that some participants may not have received their study doses with food. In addition, we do not have data on when participants took their doses relative to prenatal vitamin doses, which contain minerals that may also impair elvitegravir/cobicistat absorption [11] . Finally, infant washout analysis included wide sampling windows with sparse time points.
In light of the reduced elvitegravir exposure observed in this study, higher or more frequent elvitegravir dosing may be required during pregnancy. However, elvitegravir is primarily used as a component of a fixed dose combination tablet which does not provide dosing flexibility. Elvitegravir alone (Vitekta) was approved by the US FDA in 2012 as 85 and 150 mg tablets, but the manufacture of these formulations was permanently discontinued in 2016. Another approach to overcoming low elvitegravir exposure would be to increase the cobicistat dose. This option may be preferable as inhibition of CYP3A activity is more likely to maintain higher elvitegravir C min concentrations which are important to antiviral activity. Cobicistat is also used primarily as a component of fixed dose combinations yet it is available in an FDA-approved single agent formulation (Tybost).
To conclude, standard elvitegravir/cobicistat dosing during pregnancy results in significantly lower exposure during pregnancy which may increase the risk of virologic failure and mother-to-child transmission. Additional studies are needed to optimize elvitegravir/cobicistat dosing regimens in pregnant women.
